Toggle menu

EMERGE Biobank

Start date:
June 2013
End date:
December 2015
Co-ordinated by:
EMERGE

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

 

 Aim

To develop the infrastructure and pilot a prospective, consecutive, emergency, bioresource that will subsequently be developed for all emergency presentations

Trial Design

A pilot and feasibility programme to establish a bioresource to provide consecutive emergency samples, thus enabling investigation of the development of the acute disease/influence of disease modifiers e.g. treatment and resuscitation.

Chief Investigator

Dr Matt Reed

Local PI

Dr Matt Reed

Research Team

Paul Leonard, Sandra McGillivray, TRAK development team

Dawn Lyster, John Connolly, RIE laboratories

 

Chief Investigator

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE-CTCA Trial

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.